- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01462188
Optimizing Infarct Size by Transforming Emergent Stenting Into an Elective Procedure Study (OPTIMASTRATEGY)
Immediate Versus Delayed Stenting in Patients With ST-Elevation Myocardial Infarction Undergoing Mechanical Intervention
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
In the setting of largely thrombotic lesions such as those treated in the context of primary PCI, stenting often results in distal micro and macro-embolisation which hampers coronary flow and microvascular recovery. Interestingly in some of these studies comparing BMS versus balloon angioplasty an early hazard associated to the use of stent has been reported.
Thus, investigators hypothesize in this protocol that refraining from stenting during the acute phase of ST segment myocardial infarction is safe and associated to improved myocardial recovery as compared to acute stenting.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
Emilia Romagna
-
Ferrara, Emilia Romagna, Italien, 44100
- Rekruttering
- U.O. Cardiologia
-
Kontakt:
- Alessandro Dal Monte, MD
- Telefonnummer: +39 3487243479
- E-mail: dalmo_it@yahoo.it
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- chest pain for >30 min with ST-segment elevation of one mm or more in 2 or more contiguous ECG leads or with presumably new left bundle-branch block
- admission either within 12 h of symptom onset or between 12 and 24 h with evidence of continuing ischaemia
Exclusion Criteria:
- the exclusion criteria will include history of bleeding diathesis or documented allergy/intolerance or contraindication to clopidogrel or ticlopidine or prasugrel
- inability to assume an oral P2Y12 receptor blocker on a consecutive daily basis for a minimum of 6 months, or to heparin or aspirin
- uncontrolled hypertension (systolic or diastolic arterial pressure >180 mmHg or 120, respectively, despite medical therapy)
- limited life expectancy, e.g. neoplasms, others
- inability to obtain informed consent
- pregnancy
- patients were not enrolled if they were clinically unstable, presented with severe arrhythmia, or had known contraindications to CMR (claustrophobia, pacemakers, or implantable defibrillator devices)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Immediate stenting
Patients being randomized to the immediate stenting arm will be managed according to the guidelines.
Irrespective of TIMI flow at presentation, investigators will be requested to thrombus aspirate immediately after successful wiring of the culprit vessel followed by direct stenting.
In cases where insertion of thrombus removal catheter and/or direct stenting is not successful, balloon angioplasty will be allowed.
|
Primary coronary stenting
|
Eksperimentel: Delayed stenting
Patients being randomized to the delayed/staged stenting arm will be managed with the aim to obtain stable TIMI 3 flow with no considerations given at the percentage of residual stenosis at the culprit lesion. In patients presenting with TIMI 3 flow, investigators will be left free to wire the vessel and proceed to thrombus aspiration to decrease thrombus burden in the culprit lesion or to leave the vessel untreated at the time of index PCI. Patients presenting with suboptimal TIMI flow (i.e. less than 3), investigators are required to wire the vessel and thrombus aspirate. If stable (persisting for at least 5 minutes) TIMI 3 flow is obtained, investigators are requested to stop the procedure. The goal is to achieve s table TIMI 3 flow with no considerations given to the percentage of residual stenosis. Stenting in this arm will be allowed only on a bail-out strategy. |
Coronary stenting 3 to 7 days after having reopened the vessel in the acute phase
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Myocardial blush grade (MBG) equal or greater than 2
Tidsramme: post-procedure
|
The MBG will be estimated visually by 2 experienced observers, as previously described.
|
post-procedure
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
ST segment elevation resolution
Tidsramme: 30 minutes after the procedure
|
Cumulative ST segment elevation in all leads will be quantified before and after the procedure and expressed as percentage
|
30 minutes after the procedure
|
ST segment elevation Resolution
Tidsramme: 90 minutes after the procedure
|
90 minutes after the procedure
|
|
infarct size
Tidsramme: 5 days
|
Infarct size will be quantified by MRI
|
5 days
|
Infarct size
Tidsramme: 6 months
|
Infarct size will be quantified by MRI
|
6 months
|
microvascular obstruction
Tidsramme: 5 days
|
microvascular obstruction will be quantified by MRI
|
5 days
|
microvascular obstruction
Tidsramme: 6 months
|
microvascular obstruction will be quantified by MRI
|
6 months
|
Mortality
Tidsramme: 6 months
|
overall and cardiac mortality will be assessed up to 6 months
|
6 months
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- TRAPS-09-I
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Myokardieinfarkt
-
Sichuan Provincial People's HospitalTilmelding efter invitationRest Gated Myocardial Perfusion Imaging ved hjertesvigtKina
-
Azienda Ospedaliero Universitaria Maggiore della...Università degli Studi del Piemonte Orientale "Amedeo Avogadro"Rekruttering
-
Peking University Third HospitalAfsluttet
-
Stanford UniversitySuspenderetMyocardial brodannelseForenede Stater
-
Izmir Bakircay UniversityAfsluttetMyokardiebro af kranspulsårenKalkun
-
Fondazione Policlinico Universitario Agostino Gemelli...Afsluttet
-
ITAB - Institute for Advanced Biomedical TechnologiesAzienda Ospedaliero, Universitaria Ospedali RiunitiAfsluttetMyokardiebro af kranspulsårenItalien
-
Centre Hospitalier Sud FrancilienAfsluttetAkut anterior koroidal infarkt (ACI) | Paramedian Pontine Infarction (IPP)Frankrig
-
RenJi HospitalAfsluttetSomatisk symptomlidelse | MyokardiebroKina
-
Imperial College LondonGuy's and St Thomas' NHS Foundation Trust; University Hospital Southampton... og andre samarbejdspartnereRekrutteringSlag | Neurokognitiv dysfunktion | Silent Cerebral Infarction | Vaskulær hjerneskadeDet Forenede Kongerige
Kliniske forsøg med Immediate stenting
-
Yonsei UniversityUkendtCholangiocarcinom, galdeblærekræft, bugspytkirtelkræftKorea, Republikken
-
Istanbul UniversityAfsluttet
-
Catharina Ziekenhuis EindhovenAfsluttet
-
Seoul National University HospitalSamsung Medical Center, Sungkyunkwan University School of Medicine; Ulsan... og andre samarbejdspartnereUkendtStabil anginaKorea, Republikken, Kina
-
Istanbul Mehmet Akif Ersoy Educational and Training...Aktiv, ikke rekrutterendeKoronararteriesygdomKalkun
-
KCRISpectranetics CorporationAfsluttet
-
Indiana UniversityRekrutteringEsophageal Perforation | Esophageal fistelForenede Stater
-
Boston Scientific CorporationAfsluttetMyokardieinfarktItalien
-
Nanjing First Hospital, Nanjing Medical UniversityRekrutteringKoronararteriesygdomKina
-
be MedicalAfsluttetAterosklerotisk hjertesygdomBelgien